DK3439665T3 - Behandling af kognitive og sindsstemningssymptomer ved neurodegenerative og neuropsykiatriske lidelser med alpha5-holdige gabaa-receptoragonister - Google Patents
Behandling af kognitive og sindsstemningssymptomer ved neurodegenerative og neuropsykiatriske lidelser med alpha5-holdige gabaa-receptoragonister Download PDFInfo
- Publication number
- DK3439665T3 DK3439665T3 DK17767701.0T DK17767701T DK3439665T3 DK 3439665 T3 DK3439665 T3 DK 3439665T3 DK 17767701 T DK17767701 T DK 17767701T DK 3439665 T3 DK3439665 T3 DK 3439665T3
- Authority
- DK
- Denmark
- Prior art keywords
- neurodegenerate
- alpha5
- cognitive
- treatment
- receptor agonists
- Prior art date
Links
- 102000027484 GABAA receptors Human genes 0.000 title 1
- 108091008681 GABAA receptors Proteins 0.000 title 1
- 230000001149 cognitive effect Effects 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310409P | 2016-03-18 | 2016-03-18 | |
| PCT/US2017/023206 WO2017161370A1 (en) | 2016-03-18 | 2017-03-20 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3439665T3 true DK3439665T3 (da) | 2022-09-26 |
Family
ID=59851645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17767701.0T DK3439665T3 (da) | 2016-03-18 | 2017-03-20 | Behandling af kognitive og sindsstemningssymptomer ved neurodegenerative og neuropsykiatriske lidelser med alpha5-holdige gabaa-receptoragonister |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10906909B2 (da) |
| EP (2) | EP3439665B1 (da) |
| JP (2) | JP7023876B2 (da) |
| AU (2) | AU2017235665B2 (da) |
| CA (1) | CA3016491A1 (da) |
| DK (1) | DK3439665T3 (da) |
| ES (1) | ES2926918T3 (da) |
| HR (1) | HRP20221098T1 (da) |
| HU (1) | HUE059774T2 (da) |
| LT (1) | LT3439665T (da) |
| PL (1) | PL3439665T3 (da) |
| PT (1) | PT3439665T (da) |
| RS (1) | RS63674B1 (da) |
| SI (1) | SI3439665T1 (da) |
| WO (1) | WO2017161370A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017313753B2 (en) | 2016-08-16 | 2022-01-27 | The Trustees Of Columbia University In The City Of New York | GABA(A) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma |
| CA3129749A1 (en) * | 2019-02-13 | 2020-08-20 | Centre For Addiction And Mental Health | Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors |
| SG11202109526PA (en) * | 2019-03-18 | 2021-10-28 | Neurocycle Therapeutics Inc | Use of gabaa receptor modulators for treatment of pain |
| TW202202495A (zh) | 2020-03-26 | 2022-01-16 | 匈牙利商羅特格登公司 | 作為ｇａｍｍａ－胺基丁酸Ａ受體次單元ａｌｐｈａ ５受體調節劑之㖠啶及吡啶并〔３，４－ｃ〕嗒𠯤衍生物 |
| WO2023039018A1 (en) * | 2021-09-08 | 2023-03-16 | Uwm Research Foundation, Inc. | Imidazobenzodiazepines for treatment of cognitive and mood symptoms |
| HUP2100338A1 (hu) | 2021-09-29 | 2023-04-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
| CA3233966A1 (en) * | 2021-10-07 | 2023-04-13 | Douglas C. Stafford | Methods and compounds for treating inflammation |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA755418B (en) | 1974-09-11 | 1977-06-29 | Hoffmann La Roche | Diazepine derivatives |
| US4226768A (en) | 1979-05-29 | 1980-10-07 | Hoffmann-La Roche Inc. | Process for the preparation of imidazobenzodiazepines |
| US20030176456A1 (en) | 2001-12-21 | 2003-09-18 | June Harry L. | Methods for reducing alcohol cravings in chronic alcoholics |
| US8835424B2 (en) * | 2002-03-28 | 2014-09-16 | Wisconsin Alumni Research Foundation | Selective agents for pain suppression |
| MXPA04009332A (es) | 2002-03-28 | 2005-12-12 | Wisys Technology Found Inc | Agentes ansioliticos con efectos sedantes y ataxicos. |
| USRE47475E1 (en) | 2002-03-28 | 2019-07-02 | Wisys Technology Foundation, Inc. | Selective agents for pain suppression |
| AU2005260650A1 (en) * | 2004-06-30 | 2006-01-12 | Wisys Technology Foundation, Inc. | Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects |
| EP1888594A2 (en) * | 2005-05-16 | 2008-02-20 | Wisys Technology Foundation, Inc. | Gabaergic agents to treat memory deficits |
| US20100130479A1 (en) | 2005-05-16 | 2010-05-27 | Cook James M | Gabaergic Agents to Treat Memory Deficits |
| WO2007042544A2 (en) | 2005-10-14 | 2007-04-19 | Neurosearch A/S | Imidazole derivatives and their use for modulating the gabaa receptor complex |
| DE102006023554A1 (de) | 2006-05-19 | 2007-11-22 | Zf Friedrichshafen Ag | Ermittlung der Drehzahl einer Getriebewelle |
| US8119629B2 (en) * | 2007-10-03 | 2012-02-21 | Bristol-Meyers Squibb Company | Carboxamide GABAA α2 modulators |
| US8923318B2 (en) | 2008-10-02 | 2014-12-30 | Telefonaktiebolaget L M Ericsson (Publ) | Wireless communication system and method for assigning a channel in said wireless communication system |
| US20100261711A1 (en) | 2009-03-20 | 2010-10-14 | Wisys Technology Foundation | Selective anticonvulsant agents and their uses |
| US9006233B2 (en) * | 2011-04-28 | 2015-04-14 | Uwm Research Foundation, Inc. | Gabaergic receptor subtype selective ligands and their uses |
| JP2015529254A (ja) | 2012-09-21 | 2015-10-05 | ユーダブリューエム・リサーチ・ファウンデーション，インコーポレーテッド | 喘息における気道の過敏症及び炎症を制御するための新規なｇａｂａａアゴニスト及び使用方法 |
| US10259815B2 (en) | 2015-03-20 | 2019-04-16 | Uwm Research Foundation, Inc. | Gabaergic ligands and their uses |
-
2017
- 2017-03-20 PT PT177677010T patent/PT3439665T/pt unknown
- 2017-03-20 PL PL17767701.0T patent/PL3439665T3/pl unknown
- 2017-03-20 HR HRP20221098TT patent/HRP20221098T1/hr unknown
- 2017-03-20 JP JP2018568186A patent/JP7023876B2/ja active Active
- 2017-03-20 LT LTEPPCT/US2017/023206T patent/LT3439665T/lt unknown
- 2017-03-20 CA CA3016491A patent/CA3016491A1/en active Pending
- 2017-03-20 HU HUE17767701A patent/HUE059774T2/hu unknown
- 2017-03-20 SI SI201731230T patent/SI3439665T1/sl unknown
- 2017-03-20 WO PCT/US2017/023206 patent/WO2017161370A1/en active Application Filing
- 2017-03-20 EP EP17767701.0A patent/EP3439665B1/en active Active
- 2017-03-20 RS RS20220892A patent/RS63674B1/sr unknown
- 2017-03-20 DK DK17767701.0T patent/DK3439665T3/da active
- 2017-03-20 ES ES17767701T patent/ES2926918T3/es active Active
- 2017-03-20 EP EP22181243.1A patent/EP4129297A1/en active Pending
- 2017-03-20 US US16/086,053 patent/US10906909B2/en active Active
- 2017-03-20 AU AU2017235665A patent/AU2017235665B2/en active Active
-
2020
- 2020-12-15 US US17/122,745 patent/US11753412B2/en active Active
-
2022
- 2022-02-08 JP JP2022017827A patent/JP2022065035A/ja active Pending
- 2022-11-23 AU AU2022275446A patent/AU2022275446A1/en active Pending
-
2023
- 2023-08-02 US US18/363,933 patent/US20240083905A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3439665A1 (en) | 2019-02-13 |
| AU2017235665B2 (en) | 2022-12-08 |
| HRP20221098T1 (hr) | 2022-11-25 |
| PL3439665T3 (pl) | 2023-01-16 |
| EP3439665B1 (en) | 2022-06-29 |
| AU2022275446A1 (en) | 2023-01-05 |
| HUE059774T2 (hu) | 2023-01-28 |
| JP2019509340A (ja) | 2019-04-04 |
| CA3016491A1 (en) | 2017-09-21 |
| SI3439665T1 (sl) | 2023-05-31 |
| LT3439665T (lt) | 2022-10-10 |
| EP4129297A1 (en) | 2023-02-08 |
| PT3439665T (pt) | 2022-09-27 |
| WO2017161370A1 (en) | 2017-09-21 |
| US20210309662A1 (en) | 2021-10-07 |
| EP3439665A4 (en) | 2019-11-27 |
| RS63674B1 (sr) | 2022-11-30 |
| US20240083905A1 (en) | 2024-03-14 |
| US11753412B2 (en) | 2023-09-12 |
| WO2017161370A8 (en) | 2018-09-27 |
| JP7023876B2 (ja) | 2022-02-22 |
| JP2022065035A (ja) | 2022-04-26 |
| US20200181146A1 (en) | 2020-06-11 |
| ES2926918T3 (es) | 2022-10-31 |
| US10906909B2 (en) | 2021-02-02 |
| AU2017235665A1 (en) | 2018-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3439665T3 (da) | Behandling af kognitive og sindsstemningssymptomer ved neurodegenerative og neuropsykiatriske lidelser med alpha5-holdige gabaa-receptoragonister | |
| DK3261640T3 (da) | 5ht-agonister til behandling af epilepsilidelser | |
| DK3224269T3 (da) | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser | |
| DK3277815T3 (da) | Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser | |
| DK3212226T3 (da) | Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser | |
| DK3172227T3 (da) | Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme | |
| DK3347016T3 (da) | Diagnosticering og behandling af angstlidelse | |
| DK3185876T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser | |
| DK3307262T3 (da) | Forbindelser til anvendelse ved behandling af neuromuskulære lidelser | |
| DK3368080T3 (da) | Behandling af nervesystemforstyrrelser ved anvendelse af kombinationer af RXR-agonister og thyreoideahormoner | |
| DK3265085T3 (da) | Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser | |
| DK3288577T3 (da) | Adiponectin-peptidomimetika til behandling af øjenlidelser | |
| DK3484423T3 (da) | Anordning til hypertermisk behandling af kløe | |
| DK3099298T3 (da) | Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner | |
| DK3426303T3 (da) | Behandling af muskellidelser med kombinationer af rxr-agonister og thyroideahormoner | |
| DK3426302T3 (da) | Behandling af autoimmunsygdomme med kombinationer af rxr-agonister og skjoldbruskkirtelhormoner | |
| DK3506904T3 (da) | Behandling af demens | |
| DK3556383T3 (da) | Plasminogen til anvendelse ved behandling af diabetes | |
| MA46061A (fr) | Traitement ascaroside de maladies auto-immunes et inflammatoires | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3261661T3 (da) | Menotropin til behandling af infertilitet | |
| DK3439661T3 (da) | Fremgangsmåder til behandling af øjenlidelser | |
| DK2928910T3 (da) | Behandling af inflammation, autoimmune og neurodegenerative sygdomme med immunosuppressive tat-derivat polypeptider | |
| HK1247282A1 (zh) | 檢測蛋白質折叠錯誤的裝置及其使用方法 | |
| DK3206692T3 (da) | Behandling af fedtleversygdom med glucocorticoid- og mineralcorticoid-receptorantagonister |